Oral In-Situ Nanoplatform with Balanced Hydrophobic-Hydrophilic Property for Transport Across Gastrointestinal Mucosa
Transport of oral nanocarriers across the GI epithelium necessitates transport across hydrophilic mucus layer and the hydrophobic epithelium. Based on hydrophobic-hydrophilic balance, Curcumin-Lipomer (lipid-polymer hybrid nanoparticles) comprising hydrophobic stearic acid and hydrophilic Gantrez™ A...
Saved in:
Published in | AAPS PharmSciTech Vol. 25; no. 5; p. 113 |
---|---|
Main Authors | , , |
Format | Journal Article |
Language | English |
Published |
Cham
Springer International Publishing
15.05.2024
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Transport of oral nanocarriers across the GI epithelium necessitates transport across hydrophilic mucus layer and the hydrophobic epithelium. Based on hydrophobic-hydrophilic balance, Curcumin-Lipomer (lipid-polymer hybrid nanoparticles) comprising hydrophobic stearic acid and hydrophilic Gantrez™ AN 119 (Gantrez) were developed, by a radical
in-situ
approach, to successfully traverse both barriers. A monophasic preconcentrate (Cur-Pre) comprising Cur (Curcumin), stearic acid, Gantrez and stabilizers, prepared by simple solution, was added to an aqueous phase to instantaneously generate Curcumin-Lipomer (Cur-Lipo) of nanosize and high entrapment efficiency (EE). Cur-Lipo size and EE was optimized by Box-Behnken Design. Cur-Lipomers of varying hydrophobic-hydrophilic property obtained by varying the stearic acid: Gantrez ratio exhibited size in the range 200–400 nm, EE > 95% and spherical morphology as seen in the TEM. A decrease in contact angle and in mucus interaction, evident with increase in Gantrez concentration, indicated an inverse corelation with hydrophilicity, while a linear corelation was observed for mucopenetration and hydrophilicity. Cur-SLN (solid lipid nanoparticles) which served as the hydrophobic reference revealed contact angle > 90°, maximum interaction with mucus and minimal mucopenetration. The
ex-vivo
permeation study through chicken ileum, revealed maximum permeation with Cur-Lipo1 and comparable and significantly lower permeation of Cur-Lipo1-D and Cur-SLN proposing the importance of balancing the hydrophobic-hydrophilic property of the nanoparticles. A 1.78-fold enhancement in flux of hydrophobic Cur-SLN, with no significant change in permeation of the hydrophilic Cur-Lipomers (
p
> 0.05) following stripping off the mucosal layer was observed. This reiterated the significance of hydrophobic-hydrophilic balance as a promising strategy to design nanoformulations with superior permeation across the GI barrier.
Graphical Abstract |
---|---|
AbstractList | Transport of oral nanocarriers across the GI epithelium necessitates transport across hydrophilic mucus layer and the hydrophobic epithelium. Based on hydrophobic-hydrophilic balance, Curcumin-Lipomer (lipid-polymer hybrid nanoparticles) comprising hydrophobic stearic acid and hydrophilic Gantrez™ AN 119 (Gantrez) were developed, by a radical in-situ approach, to successfully traverse both barriers. A monophasic preconcentrate (Cur-Pre) comprising Cur (Curcumin), stearic acid, Gantrez and stabilizers, prepared by simple solution, was added to an aqueous phase to instantaneously generate Curcumin-Lipomer (Cur-Lipo) of nanosize and high entrapment efficiency (EE). Cur-Lipo size and EE was optimized by Box-Behnken Design. Cur-Lipomers of varying hydrophobic-hydrophilic property obtained by varying the stearic acid: Gantrez ratio exhibited size in the range 200-400 nm, EE > 95% and spherical morphology as seen in the TEM. A decrease in contact angle and in mucus interaction, evident with increase in Gantrez concentration, indicated an inverse corelation with hydrophilicity, while a linear corelation was observed for mucopenetration and hydrophilicity. Cur-SLN (solid lipid nanoparticles) which served as the hydrophobic reference revealed contact angle > 90°, maximum interaction with mucus and minimal mucopenetration. The ex-vivo permeation study through chicken ileum, revealed maximum permeation with Cur-Lipo1 and comparable and significantly lower permeation of Cur-Lipo1-D and Cur-SLN proposing the importance of balancing the hydrophobic-hydrophilic property of the nanoparticles. A 1.78-fold enhancement in flux of hydrophobic Cur-SLN, with no significant change in permeation of the hydrophilic Cur-Lipomers (p > 0.05) following stripping off the mucosal layer was observed. This reiterated the significance of hydrophobic-hydrophilic balance as a promising strategy to design nanoformulations with superior permeation across the GI barrier.Transport of oral nanocarriers across the GI epithelium necessitates transport across hydrophilic mucus layer and the hydrophobic epithelium. Based on hydrophobic-hydrophilic balance, Curcumin-Lipomer (lipid-polymer hybrid nanoparticles) comprising hydrophobic stearic acid and hydrophilic Gantrez™ AN 119 (Gantrez) were developed, by a radical in-situ approach, to successfully traverse both barriers. A monophasic preconcentrate (Cur-Pre) comprising Cur (Curcumin), stearic acid, Gantrez and stabilizers, prepared by simple solution, was added to an aqueous phase to instantaneously generate Curcumin-Lipomer (Cur-Lipo) of nanosize and high entrapment efficiency (EE). Cur-Lipo size and EE was optimized by Box-Behnken Design. Cur-Lipomers of varying hydrophobic-hydrophilic property obtained by varying the stearic acid: Gantrez ratio exhibited size in the range 200-400 nm, EE > 95% and spherical morphology as seen in the TEM. A decrease in contact angle and in mucus interaction, evident with increase in Gantrez concentration, indicated an inverse corelation with hydrophilicity, while a linear corelation was observed for mucopenetration and hydrophilicity. Cur-SLN (solid lipid nanoparticles) which served as the hydrophobic reference revealed contact angle > 90°, maximum interaction with mucus and minimal mucopenetration. The ex-vivo permeation study through chicken ileum, revealed maximum permeation with Cur-Lipo1 and comparable and significantly lower permeation of Cur-Lipo1-D and Cur-SLN proposing the importance of balancing the hydrophobic-hydrophilic property of the nanoparticles. A 1.78-fold enhancement in flux of hydrophobic Cur-SLN, with no significant change in permeation of the hydrophilic Cur-Lipomers (p > 0.05) following stripping off the mucosal layer was observed. This reiterated the significance of hydrophobic-hydrophilic balance as a promising strategy to design nanoformulations with superior permeation across the GI barrier. Transport of oral nanocarriers across the GI epithelium necessitates transport across hydrophilic mucus layer and the hydrophobic epithelium. Based on hydrophobic-hydrophilic balance, Curcumin-Lipomer (lipid-polymer hybrid nanoparticles) comprising hydrophobic stearic acid and hydrophilic Gantrez™ AN 119 (Gantrez) were developed, by a radical in-situ approach, to successfully traverse both barriers. A monophasic preconcentrate (Cur-Pre) comprising Cur (Curcumin), stearic acid, Gantrez and stabilizers, prepared by simple solution, was added to an aqueous phase to instantaneously generate Curcumin-Lipomer (Cur-Lipo) of nanosize and high entrapment efficiency (EE). Cur-Lipo size and EE was optimized by Box-Behnken Design. Cur-Lipomers of varying hydrophobic-hydrophilic property obtained by varying the stearic acid: Gantrez ratio exhibited size in the range 200–400 nm, EE > 95% and spherical morphology as seen in the TEM. A decrease in contact angle and in mucus interaction, evident with increase in Gantrez concentration, indicated an inverse corelation with hydrophilicity, while a linear corelation was observed for mucopenetration and hydrophilicity. Cur-SLN (solid lipid nanoparticles) which served as the hydrophobic reference revealed contact angle > 90°, maximum interaction with mucus and minimal mucopenetration. The ex-vivo permeation study through chicken ileum, revealed maximum permeation with Cur-Lipo1 and comparable and significantly lower permeation of Cur-Lipo1-D and Cur-SLN proposing the importance of balancing the hydrophobic-hydrophilic property of the nanoparticles. A 1.78-fold enhancement in flux of hydrophobic Cur-SLN, with no significant change in permeation of the hydrophilic Cur-Lipomers ( p > 0.05) following stripping off the mucosal layer was observed. This reiterated the significance of hydrophobic-hydrophilic balance as a promising strategy to design nanoformulations with superior permeation across the GI barrier. Graphical Abstract Transport of oral nanocarriers across the GI epithelium necessitates transport across hydrophilic mucus layer and the hydrophobic epithelium. Based on hydrophobic-hydrophilic balance, Curcumin-Lipomer (lipid-polymer hybrid nanoparticles) comprising hydrophobic stearic acid and hydrophilic Gantrez™ AN 119 (Gantrez) were developed, by a radical in-situ approach, to successfully traverse both barriers. A monophasic preconcentrate (Cur-Pre) comprising Cur (Curcumin), stearic acid, Gantrez and stabilizers, prepared by simple solution, was added to an aqueous phase to instantaneously generate Curcumin-Lipomer (Cur-Lipo) of nanosize and high entrapment efficiency (EE). Cur-Lipo size and EE was optimized by Box-Behnken Design. Cur-Lipomers of varying hydrophobic-hydrophilic property obtained by varying the stearic acid: Gantrez ratio exhibited size in the range 200-400 nm, EE > 95% and spherical morphology as seen in the TEM. A decrease in contact angle and in mucus interaction, evident with increase in Gantrez concentration, indicated an inverse corelation with hydrophilicity, while a linear corelation was observed for mucopenetration and hydrophilicity. Cur-SLN (solid lipid nanoparticles) which served as the hydrophobic reference revealed contact angle > 90°, maximum interaction with mucus and minimal mucopenetration. The ex-vivo permeation study through chicken ileum, revealed maximum permeation with Cur-Lipo1 and comparable and significantly lower permeation of Cur-Lipo1-D and Cur-SLN proposing the importance of balancing the hydrophobic-hydrophilic property of the nanoparticles. A 1.78-fold enhancement in flux of hydrophobic Cur-SLN, with no significant change in permeation of the hydrophilic Cur-Lipomers (p > 0.05) following stripping off the mucosal layer was observed. This reiterated the significance of hydrophobic-hydrophilic balance as a promising strategy to design nanoformulations with superior permeation across the GI barrier. |
ArticleNumber | 113 |
Author | Jayakumar, S. Attar, Esha S. Devarajan, Padma V. |
Author_xml | – sequence: 1 givenname: Esha S. surname: Attar fullname: Attar, Esha S. organization: Department of Pharmaceutical Sciences and Technology, Institute of Chemical Technology Matunga (E) – sequence: 2 givenname: S. surname: Jayakumar fullname: Jayakumar, S. organization: Radiation Biology and Health Sciences Division, Modular Laboratories, Bhabha Atomic Research Centre, Homi Bhabha National Institute – sequence: 3 givenname: Padma V. orcidid: 0000-0002-5701-3107 surname: Devarajan fullname: Devarajan, Padma V. email: pvdevarajan@gmail.com organization: Department of Pharmaceutical Sciences and Technology, Institute of Chemical Technology Matunga (E) |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/38750336$$D View this record in MEDLINE/PubMed |
BookMark | eNp9kMtOAyEYhYnR2FZ9AReGpZtRBuYCy2q0NqmXRF0TYBhLM4URmJi-vWirceUCOAnn_By-Cdi3zmoATnN0kWNEL0OOccEyhIu0aNrpHhjnJUEZYwTv_9EjMAlhhRAmOSOHYERoXSJCqjEYHr3o4NxmzyYO8EFY13cits6v4YeJS3glOmGVbuDdpvGuXzppVLbTpjMKPiWlfdzAlIEvXtjQOx_hVHkXApyJEL0zNuoQjU0v3Q_KBXEMDlrRBX2yO4_A6-3Ny_Vdtnicza-ni0xhRmNWFwzLQlQNaguZE9lKQlmORNOgokZa1A1mtUztKKEK0wq3bVnVslW6LktZNeQInG_n9t69D6kDX5ugdJf-pN0QOEFlSRkpWJ2seGv9Lu51y3tv1sJveI74F26-xc0Tbv6Nm9MUOtvNH-RaN7-RH77JQLaGkK7sm_Z85QafQIT_xn4Chk-PbA |
Cites_doi | 10.1016/j.apsb.2022.10.020 10.1021/acsami.8b18107 10.1021/la702680x 10.1126/sciadv.1601556 10.1080/17425247.2018.1420055 10.1016/j.addr.2005.07.008 10.1002/btm2.10112 10.1023/A:1019854327540 10.1166/jnn.2014.9015 10.2217/nnm.12.129 10.1016/j.ijpharm.2020.120181 10.1002/smll.201201789 10.1016/j.carbpol.2015.10.021 10.2174/138920013804545133 10.1016/j.addr.2011.12.009 10.1016/j.addr.2017.07.015 10.1021/acsami.6b08183 10.1016/j.addr.2017.10.001 10.1021/acsnano.3c02403 10.1016/j.colsurfb.2014.07.037 10.1016/j.ejpb.2015.01.005 10.1016/j.medidd.2021.100110 10.1016/j.nano.2016.08.025 10.1016/j.ijpharm.2017.09.040 10.1038/nrd.2018.183 10.1021/la010444o 10.1016/j.cej.2021.132107 10.1016/j.jconrel.2022.07.030 10.1016/j.ejpb.2014.12.024 10.1016/j.jcis.2020.08.010 10.1038/s41467-021-21989-5 10.1016/j.jconrel.2017.12.034 10.2217/nnm.09.110 10.1016/j.ijpharm.2017.09.018 10.1016/j.addr.2017.12.006 10.1039/C3CS60436E 10.1002/adma.201201800 10.17756/jfcn.2017-046 10.1016/j.ejpb.2015.05.004 10.1016/j.ijpharm.2021.120511 10.1016/j.jddst.2022.103162 10.1038/s41467-018-05061-3 10.1016/j.aca.2007.07.011 10.1016/j.ijpharm.2015.04.073 10.1016/j.addr.2017.10.004 10.1016/j.jconrel.2020.01.006 10.1016/j.ijpharm.2012.02.042 10.1016/j.jconrel.2021.04.026 10.1016/j.addr.2018.01.001 10.1002/chem.200903335 10.1016/j.addr.2017.08.010 10.1002/9781119414018.ch5 10.22028/D291-22833 10.1002/anie.201006849 |
ContentType | Journal Article |
Copyright | The Author(s), under exclusive licence to American Association of Pharmaceutical Scientists 2024. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. 2024. The Author(s), under exclusive licence to American Association of Pharmaceutical Scientists. |
Copyright_xml | – notice: The Author(s), under exclusive licence to American Association of Pharmaceutical Scientists 2024. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. – notice: 2024. The Author(s), under exclusive licence to American Association of Pharmaceutical Scientists. |
DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 |
DOI | 10.1208/s12249-024-02824-8 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef MEDLINE - Academic |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Pharmacy, Therapeutics, & Pharmacology |
EISSN | 1530-9932 |
ExternalDocumentID | 10_1208_s12249_024_02824_8 38750336 |
Genre | Journal Article |
GroupedDBID | --- -56 -5G -BR -EM -~C .86 .VR 06C 06D 0R~ 0VY 1N0 203 23M 29~ 2J2 2JN 2JY 2KG 2KM 2LR 2~H 30V 406 408 40D 40E 53G 5GY 5VS 67N 6J9 6NX 875 8TC 8UJ 95- 95. 95~ 96X AAAVM AABHQ AACDK AAHNG AAIAL AAJBT AAJKR AAKDD AANZL AARTL AASML AATNV AATVU AAUYE AAWCG AAYIU AAYQN AAYTO ABAKF ABDZT ABECU ABFGW ABFTV ABHLI ABHQN ABJNI ABJOX ABKCH ABMNI ABMQK ABNWP ABPLI ABQBU ABSXP ABTEG ABTHY ABTKH ABTMW ABWNU ABXPI ACAOD ACDTI ACGFO ACGFS ACHSB ACIPQ ACKNC ACMDZ ACMJI ACMLO ACOKC ACOMO ACREN ACSNA ACWMK ACZOJ ADBBV ADHHG ADHIR ADINQ ADKNI ADKPE ADRFC ADURQ ADYFF ADYOE ADZKW AEFQL AEGAL AEGNC AEJHL AEJRE AEMSY AENEX AEOHA AEPYU AESKC AESTI AETLH AEVLU AEVTX AEXYK AFBBN AFLOW AFQWF AFWTZ AFYQB AFZKB AGAYW AGDGC AGMZJ AGQEE AGQMX AGRTI AGWZB AGYKE AHAVH AHBYD AHKAY AHYZX AIAKS AIGIU AIIXL AILAN AIMYW AITGF AJRNO AJZVZ AKMHD AKQUC ALMA_UNASSIGNED_HOLDINGS ALWAN AMKLP AMTXH AMXSW AMYLF AMYQR AOCGG ARMRJ AXYYD B-. BA0 BAWUL BGNMA CS3 CSCUP DDRTE DNIVK DPUIP E3Z EBLON EBS EIOEI EMOBN ESBYG F5P FERAY FFXSO FIGPU FNLPD FRRFC FWDCC G-Y G-Z GGCAI GGRSB GJIRD GNWQR GQ6 GQ7 HG6 HMJXF HRMNR IJ- IKXTQ IWAJR IXC IXD I~X I~Z J-C J0Z JBSCW JZLTJ KOV KPH LGEZI LLZTM LOTEE M4Y MA- NADUK NPVJJ NQJWS NU0 NXXTH O93 O9I O9J OK1 P2P PF0 PT4 QOR QOS R89 R9I ROL RPM RPX RSV S16 S1Z S27 S3A S3B SAP SBL SHX SISQX SJYHP SNE SNPRN SNX SOHCF SOJ SPISZ SRMVM SSLCW SSXJD STPWE SZN T13 TR2 TSG TSV TUC U2A U9L UG4 UNUBA UOJIU UTJUX UZXMN VC2 VFIZW W48 WK8 XSB YLTOR Z45 Z7U Z7V Z7W Z7X Z81 Z87 ZMTXR ZOVNA ~A9 AAYZH CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 |
ID | FETCH-LOGICAL-c298t-7492b4a6d0f4b13bfb38910add0470ea7d297bced838c2862ff567bfce755b6d3 |
IEDL.DBID | AGYKE |
ISSN | 1530-9932 |
IngestDate | Sat Oct 26 04:07:44 EDT 2024 Thu Sep 12 20:28:21 EDT 2024 Tue Oct 29 09:07:37 EDT 2024 Wed Sep 04 01:21:03 EDT 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 5 |
Keywords | transepithelial transport lipomer hydrophobic-hydrophilic balance approach mucopenetration curcumin in-situ approach |
Language | English |
License | 2024. The Author(s), under exclusive licence to American Association of Pharmaceutical Scientists. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c298t-7492b4a6d0f4b13bfb38910add0470ea7d297bced838c2862ff567bfce755b6d3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ORCID | 0000-0002-5701-3107 |
PMID | 38750336 |
PQID | 3055893497 |
PQPubID | 23479 |
ParticipantIDs | proquest_miscellaneous_3055893497 crossref_primary_10_1208_s12249_024_02824_8 pubmed_primary_38750336 springer_journals_10_1208_s12249_024_02824_8 |
PublicationCentury | 2000 |
PublicationDate | 2024-05-15 |
PublicationDateYYYYMMDD | 2024-05-15 |
PublicationDate_xml | – month: 05 year: 2024 text: 2024-05-15 day: 15 |
PublicationDecade | 2020 |
PublicationPlace | Cham |
PublicationPlace_xml | – name: Cham – name: United States |
PublicationSubtitle | An Official Journal of the American Association of Pharmaceutical Scientists |
PublicationTitle | AAPS PharmSciTech |
PublicationTitleAbbrev | AAPS PharmSciTech |
PublicationTitleAlternate | AAPS PharmSciTech |
PublicationYear | 2024 |
Publisher | Springer International Publishing |
Publisher_xml | – name: Springer International Publishing |
References | Teubl, Meindl, Eitzlmayr, Zimmer, Fröhlich, Roblegg (CR54) 2013; 9 Valamla, Thakor, Phuse, Dalvi, Kharat, Kumar (CR27) 2022; 70 Khutoryanskiy (CR21) 2018; 124 Todke, Devarajan (CR39) 2022; 349 de Sousa, Steiner, Schmutzler, Wilcox, Veldhuis, Pearson (CR49) 2015; 97 Jindal, Devarajan (CR36) 2015; 489 Takeuchi, Thongborisute, Matsui, Sugihara, Yamamoto, Kawashima (CR48) 2005; 57 Azioune, Chehimi, Miksa, Basinska, Slomkowski (CR44) 2002; 18 Ren, Wu, Zhang (CR51) 2023; 13 Leal, Smyth, Ghosh (CR12) 2017; 532 Liu, Jiang, Gan, Yu (CR17) 2021; 12 Huckaby, Lai (CR9) 2018; 124 Gao, He, Zhang, Zhang, Gao, Wang (CR20) 2021; 582 Hu, Pei, Duan, Zhu, Liu, Chen (CR33) 2021; 12 Ensign, Schneider, Suk, Cone, Hanes (CR19) 2012; 24 Svensson, Thuresson, Arnebrant (CR47) 2008; 24 Dos Santos, Carvalho, Meneguin, Sábio, Gremião, Chorilli (CR52) 2021; 334 Zhang, Cheng, Dong, Zhang, Liu, Wang (CR24) 2018; 272 Ensign, Cone, Hanes (CR8) 2012; 64 Nordgård, Draget (CR46) 2018; 124 John, Dalal, Shankarkumar, Devarajan (CR38) 2021; 600 Mo, Jiang, Di, Tai, Gu (CR6) 2014; 43 Joshi, Patwardhan, Sharma, Sandur, Devarajan (CR30) 2021; 595 Anselmo, Gokarn, Mitragotri (CR15) 2019; 18 Mittal, Patel, Jhaveri, Kay, Debs, Parrish (CR2) 2018; 15 Wu, Shan, Zhang, Huang (CR23) 2018; 124 Homayouni, Sadeghi, Varshosaz, Garekani, Nokhodchi (CR42) 2014; 122 Chater, Wilcox, Pearson (CR45) 2018; 124 Kapse, Gaikwad, Samad, Devarajan (CR37) 2012; 429 CR18 Westerhout, Bellmann, van Ee, Havenaar, Leeman, Steeg (CR34) 2017; 3 Menzel, Bernkop-Schnürch (CR11) 2018; 124 CR14 CR13 Fang, Wang, Yao, Zhang, Wu, Li (CR25) 2017; 13 Griffiths, Cattoz, Ibrahim, Anuonye (CR50) 2015; 97 Crick, Parkin (CR43) 2010; 16 Ejazi, Louisthelmy, Maisel (CR1) 2023; 17 Forier, Messiaen, Raemdonck, Deschout, Rejman, De Baets (CR26) 2013; 8 D'Souza, Devarajan (CR40) 2016; 136 Roger, Lagarce, Garcion, Benoit (CR4) 2010; 5 Bachhav, Dighe, Kotak, Devarajan (CR3) 2017; 532 Grießinger, Dünnhaupt, Cattoz, Griffiths, Oh, Igómez (CR32) 2015; 96 Schneider, Xu, Boylan, Chisholm, Tang, Schuster (CR22) 2017; 3 Hu, Yang, Wang, Wang, He, Tang (CR28) 2022; 428 Froehlich, Roblegg (CR53) 2014; 14 Shan, Zhu, Tao, Cui, Liu, Wu (CR7) 2016; 8 Behrens, Pena, Alonso, Kissel (CR35) 2002; 19 Ferreira, Bruns, Ferreira, Matos, David, Brandão (CR41) 2007; 597 Poinard, Kamaluddin, Tan, Neoh, Kah (CR31) 2019; 11 Shahbazi, Santos (CR5) 2013; 14 Yu, Xu, Tian, Su, Zheng, Yang (CR10) 2018; 9 Jahagirdar, Gupta, Kulkarni, Devarajan (CR29) 2019; 4 Macedo, Castro, Roque, Thomé, Reis, Pintado (CR16) 2020; 320 2824_CR18 2824_CR14 2824_CR13 PA Todke (2824_CR39) 2022; 349 O Svensson (2824_CR47) 2008; 24 W Shan (2824_CR7) 2016; 8 IP de Sousa (2824_CR49) 2015; 97 Y Ren (2824_CR51) 2023; 13 X Zhang (2824_CR24) 2018; 272 AA D'Souza (2824_CR40) 2016; 136 K Forier (2824_CR26) 2013; 8 CT Nordgård (2824_CR46) 2018; 124 LM Ensign (2824_CR8) 2012; 64 L Wu (2824_CR23) 2018; 124 CR Crick (2824_CR43) 2010; 16 SS Bachhav (2824_CR3) 2017; 532 AM Dos Santos (2824_CR52) 2021; 334 R Mittal (2824_CR2) 2018; 15 H Takeuchi (2824_CR48) 2005; 57 PS Jahagirdar (2824_CR29) 2019; 4 B Poinard (2824_CR31) 2019; 11 B Valamla (2824_CR27) 2022; 70 CS Schneider (2824_CR22) 2017; 3 Y Gao (2824_CR20) 2021; 582 HA Joshi (2824_CR30) 2021; 595 AS Macedo (2824_CR16) 2020; 320 AB Jindal (2824_CR36) 2015; 489 AC Anselmo (2824_CR15) 2019; 18 L Fang (2824_CR25) 2017; 13 PI Chater (2824_CR45) 2018; 124 BJ Teubl (2824_CR54) 2013; 9 VV Khutoryanskiy (2824_CR21) 2018; 124 C Liu (2824_CR17) 2021; 12 J Leal (2824_CR12) 2017; 532 E Roger (2824_CR4) 2010; 5 A Azioune (2824_CR44) 2002; 18 R John (2824_CR38) 2021; 600 R Mo (2824_CR6) 2014; 43 S Hu (2824_CR28) 2022; 428 J Grießinger (2824_CR32) 2015; 96 PC Griffiths (2824_CR50) 2015; 97 A Homayouni (2824_CR42) 2014; 122 LM Ensign (2824_CR19) 2012; 24 E Froehlich (2824_CR53) 2014; 14 C Menzel (2824_CR11) 2018; 124 SV Kapse (2824_CR37) 2012; 429 JT Huckaby (2824_CR9) 2018; 124 I Behrens (2824_CR35) 2002; 19 M-A Shahbazi (2824_CR5) 2013; 14 J Westerhout (2824_CR34) 2017; 3 S Hu (2824_CR33) 2021; 12 SA Ejazi (2824_CR1) 2023; 17 SC Ferreira (2824_CR41) 2007; 597 M Yu (2824_CR10) 2018; 9 |
References_xml | – volume: 13 start-page: 2544 issue: 6 year: 2023 end-page: 2558 ident: CR51 article-title: The feasibility of oral targeted drug delivery: Gut immune to particulates? publication-title: Acta Pharmaceutica Sinica B doi: 10.1016/j.apsb.2022.10.020 contributor: fullname: Zhang – volume: 11 start-page: 4777 issue: 5 year: 2019 end-page: 4789 ident: CR31 article-title: Polydopamine coating enhances mucopenetration and cell uptake of nanoparticles publication-title: ACS Appl Mater Interfaces doi: 10.1021/acsami.8b18107 contributor: fullname: Kah – volume: 24 start-page: 2573 issue: 6 year: 2008 end-page: 2579 ident: CR47 article-title: Interactions between drug delivery particles and mucin in solution and at interfaces publication-title: Langmuir doi: 10.1021/la702680x contributor: fullname: Arnebrant – volume: 3 start-page: e1601556 issue: 4 year: 2017 ident: CR22 article-title: Nanoparticles that do not adhere to mucus provide uniform and long-lasting drug delivery to airways following inhalation publication-title: Sci Adv doi: 10.1126/sciadv.1601556 contributor: fullname: Schuster – volume: 15 start-page: 301 issue: 3 year: 2018 end-page: 18 ident: CR2 article-title: Recent advancements in nanoparticle based drug delivery for gastrointestinal disorders publication-title: Expert Opin Drug Deliv. doi: 10.1080/17425247.2018.1420055 contributor: fullname: Parrish – volume: 57 start-page: 1583 issue: 11 year: 2005 end-page: 1594 ident: CR48 article-title: Novel mucoadhesion tests for polymers and polymer-coated particles to design optimal mucoadhesive drug delivery systems publication-title: Adv Drug Deliv Rev doi: 10.1016/j.addr.2005.07.008 contributor: fullname: Kawashima – volume: 4 start-page: 141 issue: 1 year: 2019 end-page: 151 ident: CR29 article-title: Polymeric curcumin nanoparticles by a facile in situ method for macrophage targeted delivery publication-title: Bioeng Transl Med doi: 10.1002/btm2.10112 contributor: fullname: Devarajan – volume: 19 start-page: 1185 year: 2002 end-page: 1193 ident: CR35 article-title: Comparative uptake studies of bioadhesive and non-bioadhesive nanoparticles in human intestinal cell lines and rats: the effect of mucus on particle adsorption and transport publication-title: Pharm Res doi: 10.1023/A:1019854327540 contributor: fullname: Kissel – volume: 14 start-page: 126 issue: 1 year: 2014 end-page: 136 ident: CR53 article-title: Mucus as barrier for drug delivery by nanoparticles publication-title: J Nanosci Nanotechnol doi: 10.1166/jnn.2014.9015 contributor: fullname: Roblegg – volume: 8 start-page: 935 issue: 6 year: 2013 end-page: 949 ident: CR26 article-title: Transport of nanoparticles in cystic fibrosis sputum and bacterial biofilms by single-particle tracking microscopy publication-title: Nanomedicine doi: 10.2217/nnm.12.129 contributor: fullname: De Baets – volume: 595 start-page: 120181 year: 2021 ident: CR30 article-title: Pre-clinical evaluation of an innovative oral nano-formulation of baicalein for modulation of radiation responses publication-title: Int J Pharm doi: 10.1016/j.ijpharm.2020.120181 contributor: fullname: Devarajan – volume: 9 start-page: 457 issue: 3 year: 2013 end-page: 466 ident: CR54 article-title: In-vitro permeability of neutral polystyrene particles via buccal mucosa publication-title: Small doi: 10.1002/smll.201201789 contributor: fullname: Roblegg – volume: 136 start-page: 1251 year: 2016 end-page: 1258 ident: CR40 article-title: Bioenhanced oral curcumin nanoparticles: role of carbohydrates publication-title: Carbohyd Polym doi: 10.1016/j.carbpol.2015.10.021 contributor: fullname: Devarajan – volume: 14 start-page: 28 issue: 1 year: 2013 end-page: 56 ident: CR5 article-title: Improving oral absorption via drug-loaded nanocarriers: absorption mechanisms, intestinal models and rational fabrication publication-title: Curr Drug Metab. doi: 10.2174/138920013804545133 contributor: fullname: Santos – volume: 64 start-page: 557 issue: 6 year: 2012 end-page: 570 ident: CR8 article-title: Oral drug delivery with polymeric nanoparticles: the gastrointestinal mucus barriers publication-title: Adv Drug Deliv Rev doi: 10.1016/j.addr.2011.12.009 contributor: fullname: Hanes – volume: 124 start-page: 140 year: 2018 end-page: 149 ident: CR21 article-title: Beyond PEGylation: alternative surface-modification of nanoparticles with mucus-inert biomaterials publication-title: Adv Drug Deliv Rev doi: 10.1016/j.addr.2017.07.015 contributor: fullname: Khutoryanskiy – volume: 8 start-page: 25444 issue: 38 year: 2016 end-page: 25453 ident: CR7 article-title: Enhanced oral delivery of protein drugs using zwitterion-functionalized nanoparticles to overcome both the diffusion and absorption barriers publication-title: ACS Appl Mater Interfaces doi: 10.1021/acsami.6b08183 contributor: fullname: Wu – volume: 124 start-page: 150 year: 2018 end-page: 163 ident: CR23 article-title: Engineering nanomaterials to overcome the mucosal barrier by modulating surface properties publication-title: Adv Drug Deliv Rev doi: 10.1016/j.addr.2017.10.001 contributor: fullname: Huang – volume: 17 start-page: 13044 issue: 14 year: 2023 end-page: 13061 ident: CR1 article-title: Mechanisms of nanoparticle transport across intestinal tissue: an oral delivery perspective publication-title: ACS Nano doi: 10.1021/acsnano.3c02403 contributor: fullname: Maisel – volume: 122 start-page: 591 year: 2014 end-page: 600 ident: CR42 article-title: Promising dissolution enhancement effect of soluplus on crystallized celecoxib obtained through antisolvent precipitation and high pressure homogenization techniques publication-title: Colloids Surf B doi: 10.1016/j.colsurfb.2014.07.037 contributor: fullname: Nokhodchi – volume: 96 start-page: 464 year: 2015 end-page: 76 ident: CR32 article-title: Methods to determine the interactions of micro-and nanoparticles with mucus publication-title: Eur J Pharm Biopharm doi: 10.1016/j.ejpb.2015.01.005 contributor: fullname: Igómez – volume: 12 start-page: 100110 year: 2021 ident: CR17 article-title: Engineering nanoparticles to overcome the mucus barrier for drug delivery: Design, evaluation and state-of-the-art publication-title: Medicine in Drug Discovery doi: 10.1016/j.medidd.2021.100110 contributor: fullname: Yu – ident: CR18 – volume: 13 start-page: 153 issue: 1 year: 2017 end-page: 71 ident: CR25 article-title: Micro-and nano-carrier systems: The non-invasive and painless local administration strategies for disease therapy in mucosal tissues publication-title: Nanomedicine. doi: 10.1016/j.nano.2016.08.025 contributor: fullname: Li – volume: 532 start-page: 612 issue: 1 year: 2017 end-page: 622 ident: CR3 article-title: Rifampicin Lipid-Polymer hybrid nanoparticles (LIPOMER) for enhanced Peyer’s patch uptake publication-title: Int J Pharm doi: 10.1016/j.ijpharm.2017.09.040 contributor: fullname: Devarajan – volume: 18 start-page: 19 issue: 1 year: 2019 end-page: 40 ident: CR15 article-title: Non-invasive delivery strategies for biologics publication-title: Nat Rev Drug Discovery doi: 10.1038/nrd.2018.183 contributor: fullname: Mitragotri – volume: 18 start-page: 1150 issue: 4 year: 2002 end-page: 1156 ident: CR44 article-title: Hydrophobic protein− polypyrrole interactions: The role of van der Waals and Lewis acid− base forces as determined by contact angle measurements publication-title: Langmuir doi: 10.1021/la010444o contributor: fullname: Slomkowski – ident: CR14 – volume: 428 start-page: 132107 year: 2022 ident: CR28 article-title: Zwitterionic polydopamine modified nanoparticles as an efficient nanoplatform to overcome both the mucus and epithelial barriers publication-title: Chem Eng J doi: 10.1016/j.cej.2021.132107 contributor: fullname: Tang – volume: 349 start-page: 756 year: 2022 end-page: 764 ident: CR39 article-title: In-silico approach as a tool for selection of excipients for safer amphotericin B nanoformulations publication-title: J Control Release doi: 10.1016/j.jconrel.2022.07.030 contributor: fullname: Devarajan – volume: 97 start-page: 273 year: 2015 end-page: 279 ident: CR49 article-title: Mucus permeating carriers: formulation and characterization of highly densely charged nanoparticles publication-title: Eur J Pharm Biopharm doi: 10.1016/j.ejpb.2014.12.024 contributor: fullname: Pearson – volume: 582 start-page: 364 year: 2021 end-page: 375 ident: CR20 article-title: Zwitterion-functionalized mesoporous silica nanoparticles for enhancing oral delivery of protein drugs by overcoming multiple gastrointestinal barriers publication-title: J Colloid Interface Sci doi: 10.1016/j.jcis.2020.08.010 contributor: fullname: Wang – volume: 12 start-page: 1689 issue: 1 year: 2021 ident: CR33 article-title: A mussel-inspired film for adhesion to wet buccal tissue and efficient buccal drug delivery publication-title: Nat Commun doi: 10.1038/s41467-021-21989-5 contributor: fullname: Chen – volume: 272 start-page: 29 year: 2018 end-page: 38 ident: CR24 article-title: Design and intestinal mucus penetration mechanism of core-shell nanocomplex publication-title: J Control Release doi: 10.1016/j.jconrel.2017.12.034 contributor: fullname: Wang – volume: 5 start-page: 287 issue: 2 year: 2010 end-page: 306 ident: CR4 article-title: Biopharmaceutical parameters to consider in order to alter the fate of nanocarriers after oral delivery publication-title: Nanomedicine doi: 10.2217/nnm.09.110 contributor: fullname: Benoit – volume: 532 start-page: 555 issue: 1 year: 2017 end-page: 572 ident: CR12 article-title: Physicochemical properties of mucus and their impact on transmucosal drug delivery publication-title: Int J Pharm doi: 10.1016/j.ijpharm.2017.09.018 contributor: fullname: Ghosh – volume: 124 start-page: 184 year: 2018 end-page: 192 ident: CR45 article-title: Efficacy and safety concerns over the use of mucus modulating agents for drug delivery using nanoscale systems publication-title: Adv Drug Deliv Rev doi: 10.1016/j.addr.2017.12.006 contributor: fullname: Pearson – volume: 43 start-page: 3595 issue: 10 year: 2014 end-page: 3629 ident: CR6 article-title: Emerging micro-and nanotechnology based synthetic approaches for insulin delivery publication-title: Chem Soc Rev doi: 10.1039/C3CS60436E contributor: fullname: Gu – volume: 24 start-page: 3887 issue: 28 year: 2012 end-page: 3894 ident: CR19 article-title: Mucus penetrating nanoparticles: biophysical tool and method of drug and gene delivery publication-title: Adv Mater doi: 10.1002/adma.201201800 contributor: fullname: Hanes – volume: 3 start-page: 111 issue: 4 year: 2017 end-page: 9 ident: CR34 article-title: Prediction of oral absorption of nanoparticles from biorelevant matrices using a combination of physiologically relevant in vitro and ex vivo models publication-title: J Food Chem Nanotechnol. doi: 10.17756/jfcn.2017-046 contributor: fullname: Steeg – volume: 97 start-page: 218 year: 2015 end-page: 222 ident: CR50 article-title: Probing the interaction of nanoparticles with mucin for drug delivery applications using dynamic light scattering publication-title: Eur J Pharm Biopharm doi: 10.1016/j.ejpb.2015.05.004 contributor: fullname: Anuonye – volume: 600 year: 2021 ident: CR38 article-title: Innovative betulin nanosuspension exhibits enhanced anticancer activity in a triple negative breast cancer cell line and Zebrafish angiogenesis model publication-title: Int J Pharm doi: 10.1016/j.ijpharm.2021.120511 contributor: fullname: Devarajan – volume: 70 start-page: 103162 year: 2022 ident: CR27 article-title: Engineering drug delivery systems to overcome the vaginal mucosal barrier: Current understanding and research agenda of mucoadhesive formulations of vaginal delivery publication-title: J Drug Deliv Sci Technol doi: 10.1016/j.jddst.2022.103162 contributor: fullname: Kumar – volume: 9 start-page: 2607 issue: 1 year: 2018 ident: CR10 article-title: Rapid transport of deformation-tuned nanoparticles across biological hydrogels and cellular barriers publication-title: Nat Commun doi: 10.1038/s41467-018-05061-3 contributor: fullname: Yang – volume: 597 start-page: 179 issue: 2 year: 2007 end-page: 186 ident: CR41 article-title: Box-Behnken design: An alternative for the optimization of analytical methods publication-title: Anal Chim Acta doi: 10.1016/j.aca.2007.07.011 contributor: fullname: Brandão – volume: 489 start-page: 246 issue: 1–2 year: 2015 end-page: 251 ident: CR36 article-title: Asymmetric lipid–polymer particles (LIPOMER) by modified nanoprecipitation: role of non-solvent composition publication-title: Int J Pharm doi: 10.1016/j.ijpharm.2015.04.073 contributor: fullname: Devarajan – ident: CR13 – volume: 124 start-page: 164 year: 2018 end-page: 174 ident: CR11 article-title: Enzyme decorated drug carriers: targeted swords to cleave and overcome the mucus barrier publication-title: Adv Drug Deliv Rev doi: 10.1016/j.addr.2017.10.004 contributor: fullname: Bernkop-Schnürch – volume: 320 start-page: 125 year: 2020 end-page: 141 ident: CR16 article-title: Novel and revisited approaches in nanoparticle systems for buccal drug delivery publication-title: J Control Release doi: 10.1016/j.jconrel.2020.01.006 contributor: fullname: Pintado – volume: 429 start-page: 104 issue: 1–2 year: 2012 end-page: 112 ident: CR37 article-title: Self nanoprecipitating preconcentrate of tamoxifen citrate for enhanced bioavailability publication-title: Int J Pharm doi: 10.1016/j.ijpharm.2012.02.042 contributor: fullname: Devarajan – volume: 334 start-page: 353 year: 2021 end-page: 366 ident: CR52 article-title: Oral delivery of micro/nanoparticulate systems based on natural polysaccharides for intestinal diseases therapy: Challenges, advances and future perspectives publication-title: J Control Release doi: 10.1016/j.jconrel.2021.04.026 contributor: fullname: Chorilli – volume: 124 start-page: 175 year: 2018 end-page: 183 ident: CR46 article-title: Co association of mucus modulating agents and nanoparticles for mucosal drug delivery publication-title: Adv Drug Deliv Rev doi: 10.1016/j.addr.2018.01.001 contributor: fullname: Draget – volume: 16 start-page: 3568 issue: 12 year: 2010 end-page: 88 ident: CR43 article-title: Preparation and characterisation of super-hydrophobic surfaces publication-title: Chem Eur J. doi: 10.1002/chem.200903335 contributor: fullname: Parkin – volume: 124 start-page: 125 year: 2018 end-page: 139 ident: CR9 article-title: PEGylation for enhancing nanoparticle diffusion in mucus publication-title: Adv Drug Deliv Rev doi: 10.1016/j.addr.2017.08.010 contributor: fullname: Lai – ident: 2824_CR14 doi: 10.1002/9781119414018.ch5 – volume: 122 start-page: 591 year: 2014 ident: 2824_CR42 publication-title: Colloids Surf B doi: 10.1016/j.colsurfb.2014.07.037 contributor: fullname: A Homayouni – volume: 349 start-page: 756 year: 2022 ident: 2824_CR39 publication-title: J Control Release doi: 10.1016/j.jconrel.2022.07.030 contributor: fullname: PA Todke – volume: 595 start-page: 120181 year: 2021 ident: 2824_CR30 publication-title: Int J Pharm doi: 10.1016/j.ijpharm.2020.120181 contributor: fullname: HA Joshi – volume: 429 start-page: 104 issue: 1–2 year: 2012 ident: 2824_CR37 publication-title: Int J Pharm doi: 10.1016/j.ijpharm.2012.02.042 contributor: fullname: SV Kapse – volume: 8 start-page: 935 issue: 6 year: 2013 ident: 2824_CR26 publication-title: Nanomedicine doi: 10.2217/nnm.12.129 contributor: fullname: K Forier – volume: 8 start-page: 25444 issue: 38 year: 2016 ident: 2824_CR7 publication-title: ACS Appl Mater Interfaces doi: 10.1021/acsami.6b08183 contributor: fullname: W Shan – volume: 124 start-page: 140 year: 2018 ident: 2824_CR21 publication-title: Adv Drug Deliv Rev doi: 10.1016/j.addr.2017.07.015 contributor: fullname: VV Khutoryanskiy – volume: 320 start-page: 125 year: 2020 ident: 2824_CR16 publication-title: J Control Release doi: 10.1016/j.jconrel.2020.01.006 contributor: fullname: AS Macedo – volume: 9 start-page: 2607 issue: 1 year: 2018 ident: 2824_CR10 publication-title: Nat Commun doi: 10.1038/s41467-018-05061-3 contributor: fullname: M Yu – volume: 3 start-page: e1601556 issue: 4 year: 2017 ident: 2824_CR22 publication-title: Sci Adv doi: 10.1126/sciadv.1601556 contributor: fullname: CS Schneider – volume: 600 year: 2021 ident: 2824_CR38 publication-title: Int J Pharm doi: 10.1016/j.ijpharm.2021.120511 contributor: fullname: R John – volume: 124 start-page: 125 year: 2018 ident: 2824_CR9 publication-title: Adv Drug Deliv Rev doi: 10.1016/j.addr.2017.08.010 contributor: fullname: JT Huckaby – volume: 334 start-page: 353 year: 2021 ident: 2824_CR52 publication-title: J Control Release doi: 10.1016/j.jconrel.2021.04.026 contributor: fullname: AM Dos Santos – volume: 5 start-page: 287 issue: 2 year: 2010 ident: 2824_CR4 publication-title: Nanomedicine doi: 10.2217/nnm.09.110 contributor: fullname: E Roger – volume: 597 start-page: 179 issue: 2 year: 2007 ident: 2824_CR41 publication-title: Anal Chim Acta doi: 10.1016/j.aca.2007.07.011 contributor: fullname: SC Ferreira – volume: 489 start-page: 246 issue: 1–2 year: 2015 ident: 2824_CR36 publication-title: Int J Pharm doi: 10.1016/j.ijpharm.2015.04.073 contributor: fullname: AB Jindal – volume: 136 start-page: 1251 year: 2016 ident: 2824_CR40 publication-title: Carbohyd Polym doi: 10.1016/j.carbpol.2015.10.021 contributor: fullname: AA D'Souza – volume: 15 start-page: 301 issue: 3 year: 2018 ident: 2824_CR2 publication-title: Expert Opin Drug Deliv. doi: 10.1080/17425247.2018.1420055 contributor: fullname: R Mittal – volume: 97 start-page: 273 year: 2015 ident: 2824_CR49 publication-title: Eur J Pharm Biopharm doi: 10.1016/j.ejpb.2014.12.024 contributor: fullname: IP de Sousa – volume: 43 start-page: 3595 issue: 10 year: 2014 ident: 2824_CR6 publication-title: Chem Soc Rev doi: 10.1039/C3CS60436E contributor: fullname: R Mo – volume: 11 start-page: 4777 issue: 5 year: 2019 ident: 2824_CR31 publication-title: ACS Appl Mater Interfaces doi: 10.1021/acsami.8b18107 contributor: fullname: B Poinard – volume: 70 start-page: 103162 year: 2022 ident: 2824_CR27 publication-title: J Drug Deliv Sci Technol doi: 10.1016/j.jddst.2022.103162 contributor: fullname: B Valamla – ident: 2824_CR13 doi: 10.22028/D291-22833 – volume: 582 start-page: 364 year: 2021 ident: 2824_CR20 publication-title: J Colloid Interface Sci doi: 10.1016/j.jcis.2020.08.010 contributor: fullname: Y Gao – volume: 4 start-page: 141 issue: 1 year: 2019 ident: 2824_CR29 publication-title: Bioeng Transl Med doi: 10.1002/btm2.10112 contributor: fullname: PS Jahagirdar – volume: 64 start-page: 557 issue: 6 year: 2012 ident: 2824_CR8 publication-title: Adv Drug Deliv Rev doi: 10.1016/j.addr.2011.12.009 contributor: fullname: LM Ensign – volume: 18 start-page: 19 issue: 1 year: 2019 ident: 2824_CR15 publication-title: Nat Rev Drug Discovery doi: 10.1038/nrd.2018.183 contributor: fullname: AC Anselmo – volume: 124 start-page: 150 year: 2018 ident: 2824_CR23 publication-title: Adv Drug Deliv Rev doi: 10.1016/j.addr.2017.10.001 contributor: fullname: L Wu – volume: 96 start-page: 464 year: 2015 ident: 2824_CR32 publication-title: Eur J Pharm Biopharm doi: 10.1016/j.ejpb.2015.01.005 contributor: fullname: J Grießinger – volume: 24 start-page: 3887 issue: 28 year: 2012 ident: 2824_CR19 publication-title: Adv Mater doi: 10.1002/adma.201201800 contributor: fullname: LM Ensign – volume: 124 start-page: 175 year: 2018 ident: 2824_CR46 publication-title: Adv Drug Deliv Rev doi: 10.1016/j.addr.2018.01.001 contributor: fullname: CT Nordgård – volume: 272 start-page: 29 year: 2018 ident: 2824_CR24 publication-title: J Control Release doi: 10.1016/j.jconrel.2017.12.034 contributor: fullname: X Zhang – volume: 57 start-page: 1583 issue: 11 year: 2005 ident: 2824_CR48 publication-title: Adv Drug Deliv Rev doi: 10.1016/j.addr.2005.07.008 contributor: fullname: H Takeuchi – volume: 16 start-page: 3568 issue: 12 year: 2010 ident: 2824_CR43 publication-title: Chem Eur J. doi: 10.1002/chem.200903335 contributor: fullname: CR Crick – volume: 17 start-page: 13044 issue: 14 year: 2023 ident: 2824_CR1 publication-title: ACS Nano doi: 10.1021/acsnano.3c02403 contributor: fullname: SA Ejazi – volume: 12 start-page: 1689 issue: 1 year: 2021 ident: 2824_CR33 publication-title: Nat Commun doi: 10.1038/s41467-021-21989-5 contributor: fullname: S Hu – volume: 14 start-page: 126 issue: 1 year: 2014 ident: 2824_CR53 publication-title: J Nanosci Nanotechnol doi: 10.1166/jnn.2014.9015 contributor: fullname: E Froehlich – volume: 532 start-page: 555 issue: 1 year: 2017 ident: 2824_CR12 publication-title: Int J Pharm doi: 10.1016/j.ijpharm.2017.09.018 contributor: fullname: J Leal – volume: 532 start-page: 612 issue: 1 year: 2017 ident: 2824_CR3 publication-title: Int J Pharm doi: 10.1016/j.ijpharm.2017.09.040 contributor: fullname: SS Bachhav – volume: 9 start-page: 457 issue: 3 year: 2013 ident: 2824_CR54 publication-title: Small doi: 10.1002/smll.201201789 contributor: fullname: BJ Teubl – volume: 428 start-page: 132107 year: 2022 ident: 2824_CR28 publication-title: Chem Eng J doi: 10.1016/j.cej.2021.132107 contributor: fullname: S Hu – volume: 12 start-page: 100110 year: 2021 ident: 2824_CR17 publication-title: Medicine in Drug Discovery doi: 10.1016/j.medidd.2021.100110 contributor: fullname: C Liu – volume: 97 start-page: 218 year: 2015 ident: 2824_CR50 publication-title: Eur J Pharm Biopharm doi: 10.1016/j.ejpb.2015.05.004 contributor: fullname: PC Griffiths – volume: 24 start-page: 2573 issue: 6 year: 2008 ident: 2824_CR47 publication-title: Langmuir doi: 10.1021/la702680x contributor: fullname: O Svensson – volume: 3 start-page: 111 issue: 4 year: 2017 ident: 2824_CR34 publication-title: J Food Chem Nanotechnol. doi: 10.17756/jfcn.2017-046 contributor: fullname: J Westerhout – volume: 13 start-page: 153 issue: 1 year: 2017 ident: 2824_CR25 publication-title: Nanomedicine. doi: 10.1016/j.nano.2016.08.025 contributor: fullname: L Fang – volume: 18 start-page: 1150 issue: 4 year: 2002 ident: 2824_CR44 publication-title: Langmuir doi: 10.1021/la010444o contributor: fullname: A Azioune – volume: 124 start-page: 184 year: 2018 ident: 2824_CR45 publication-title: Adv Drug Deliv Rev doi: 10.1016/j.addr.2017.12.006 contributor: fullname: PI Chater – volume: 13 start-page: 2544 issue: 6 year: 2023 ident: 2824_CR51 publication-title: Acta Pharmaceutica Sinica B doi: 10.1016/j.apsb.2022.10.020 contributor: fullname: Y Ren – volume: 14 start-page: 28 issue: 1 year: 2013 ident: 2824_CR5 publication-title: Curr Drug Metab. doi: 10.2174/138920013804545133 contributor: fullname: M-A Shahbazi – volume: 19 start-page: 1185 year: 2002 ident: 2824_CR35 publication-title: Pharm Res doi: 10.1023/A:1019854327540 contributor: fullname: I Behrens – volume: 124 start-page: 164 year: 2018 ident: 2824_CR11 publication-title: Adv Drug Deliv Rev doi: 10.1016/j.addr.2017.10.004 contributor: fullname: C Menzel – ident: 2824_CR18 doi: 10.1002/anie.201006849 |
SSID | ssj0023193 |
Score | 2.426189 |
Snippet | Transport of oral nanocarriers across the GI epithelium necessitates transport across hydrophilic mucus layer and the hydrophobic epithelium. Based on... |
SourceID | proquest crossref pubmed springer |
SourceType | Aggregation Database Index Database Publisher |
StartPage | 113 |
SubjectTerms | Administration, Oral Animals Biochemistry Biological Transport - physiology Biomedical and Life Sciences Biomedicine Biotechnology Curcumin - administration & dosage Curcumin - chemistry Curcumin - pharmacokinetics Drug Carriers - chemistry Hydrophobic and Hydrophilic Interactions Intestinal Mucosa - metabolism Lipids - chemistry Nanoparticles - chemistry Particle Size Pharmacology/Toxicology Pharmacy Polymers - chemistry Polyvinyls - chemistry Research Article Stearic Acids - chemistry |
Title | Oral In-Situ Nanoplatform with Balanced Hydrophobic-Hydrophilic Property for Transport Across Gastrointestinal Mucosa |
URI | https://link.springer.com/article/10.1208/s12249-024-02824-8 https://www.ncbi.nlm.nih.gov/pubmed/38750336 https://www.proquest.com/docview/3055893497 |
Volume | 25 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3Nb9MwFH_auguX8T0KbPIktAv1SGMnsY8d2tYNDSrRSuNk2Y4tKqakyseh_PXY-WiFipB2yyF2kvf9_N77BeCDicx4bJ1-O3caY0ppiDlTFI-58iZZqjDw08h3X-Ppgt7eR_fbOe6m2b2vSDaGugFACNin0peAOHYuBfs0gWK2Dwd-8DQawMHk-seXy02e5aSKdPMx_175tw_aCSx3iqKNr7l6CvN-YqdtMfl1XlfqXP_eBXB8zGc8g8Mu9kSTVliew57JXsDZrAWvXo_QfDuLVY7QGZptYa3XL6H-VrjFNxn-vqxq5KxyvnqQlY95kT_MRRe-SVKbFE3XaZGvfuZqqXF3vXxYajTz5_5FtUZuDdqAqqNJQyR0LcuqyD16hTM6_jXvfC-9fAWLq8v55ynuftqAdchZhRPKQ0VlnAaWqjFRVvlKaODMaECTwMgkDXni5CBlhOnQ5VPWRnGirDZJFKk4Ja9hkOWZeQNIM-3CIWtkbBklmsnI6JgTyQwlxCo-hI89G8WqxeYQPqdxdBYtnYWjs2joLNgQTntOC6dCvi4iM5PXpfCgZy5sozwZwlErApv9CGsKvfEQRj0_Rafl5X8e9vZxt7-DJ2EjEr6R8j0MqqI2xy7YqdRJJ9wnsL8IJ38AwOD6Bw |
link.rule.ids | 315,783,787,27938,27939,41095,41537,42164,42606,52125,52248 |
linkProvider | Springer Nature |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lj9MwEB7BcoAL4k1ZHkZCe6EWSewk9rEgli5sl0q00t4s27FFpVVSJemh_349eXSFFiFxyyGT1zeeh2fmC8AHl7o49mF9B3eaUc55QqUwnMbSoEnWJolwGnlxkc3X_PtlejkMhTVjt_tYkuwsdceAEIlPDdaAJA0-hWKewKm4C_eQXx31ep3MDmlWUCo2jMf8Xe5PF3QrrrxVE-1czekjeDjEiGTWg_oY7rjyCZwse5Lp_ZSsbmammik5Icsb-un9U9j9rIPwWUl_bdodCdaz2l7pFmNTgpuu5DM2M1pXkPm-qKvt78psLB2ON1cbS5a4P1-3exJkyIH8nMy6tyHfdNPWFbJMBOOAj7nAnnf9DNanX1df5nT4uQK1iRQtzblMDNdZEXluYma8wYplFMxdxPPI6bxIZB7wKgQTNgl5j_dplhtvXZ6mJivYczgqq9K9BGKFDWGLdzrzgjMrdOpsJpkWjjPmjZzAx_F7q23PoaEw9wjoqB4dFdBRHTpKTOD9CIkKqo71C126atcoJCcL4RWX-QRe9FgdrsdEV5DNJjAdwVPDamz-cbNX_3f6O7g_Xy3O1fnZxY9jeJB0SpXSOH0NR229c29CgNKat50-XgP1ht_8 |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwEB7BVkJceD-Wp5FQL6zbJHYS57hAt1tKy0q0UjlZtmOrq1bJKnEOy6_HzmMLFCEhbjnEiTMez8PfzBeAtzrWYWjc_nbuNMGU0ghnTFIcZtKbZCGjwHcjHx0n81P66Sw--6mLv612HyDJrqfBszQVdneVm44NIWC7tceDMuz8C_Y5A8XsJmzR0IULI9ia7n873NskXU7FSN8s8-eRvzqka1HmNYS0dTyzuyCGKXf1Jhc7jZU76vtvbI7_80334E4flaJpp0b34YYuHsD2oqO1Xk_QyVWXVj1B22hxRXi9fgjNl8oNPijw16VtkLPX5epSWB8NI3_Mi9778kmlczRf51W5Oi_lUuH-enm5VGjhEYHKrpEbgzZ062jaSgzti9pWpee1cObIT_PIV9mLR3A62zv5MMf97xywijJmcUqzSFKR5IGhMiTSSI-RBs7ABjQNtEjzKEudhuSMMBW5TMuYOEmlUTqNY5nk5DGMirLQTwEpplygZLRIDKNEMRFrlWREME0JMTIbw7thTfmqY-3gPttxcuadnLmTM2_lzNkY3gzLzt3m8oiJKHTZ1NzTobmAjmbpGJ50-rB5HmEtBJyMYTKsLe_3f_2Xlz37t9tfw63Fxxn_fHB8-BxuR612xDiMX8DIVo1-6SIiK1_1Sv8DaMEF6g |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Oral+In-Situ+Nanoplatform+with+Balanced+Hydrophobic-Hydrophilic+Property+for+Transport+Across+Gastrointestinal+Mucosa&rft.jtitle=AAPS+PharmSciTech&rft.au=Attar%2C+Esha+S&rft.au=Jayakumar%2C+S&rft.au=Devarajan%2C+Padma+V&rft.date=2024-05-15&rft.issn=1530-9932&rft.eissn=1530-9932&rft.volume=25&rft.issue=5&rft.spage=113&rft_id=info:doi/10.1208%2Fs12249-024-02824-8&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1530-9932&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1530-9932&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1530-9932&client=summon |